Sorafenib In Egyptian Patients With Hepatocellular Carcinoma.
Condition: Hepatocellular Carcinoma Intervention: Drug: Sorafenib Tablets Sponsors: Damanhour University; Mransoura University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 11, 2023 Category: Research Source Type: clinical trials
Usability and Clinical Effectiveness of an Interpretable Deep Learning Framework for Post-Hepatectomy Liver Failure Prediction
Conditions: Post-hepatectomy Liver Failure; Hepatocellular Carcinoma; Artificial Intelligence Interventions: Other: The explanation of deep learning framework (VAE-MLP) , including counterfactual explanations and layerwise relevance propagation; Other: The model prediction; Other: The model prediction and the explanation of deep learning framework (VAE-MLP) , including counterfactual explanati ons and layerwise relevance propagation Sponsors: Maastricht University; First Affiliated Hospital, Sun Yat-Sen University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 11, 2023 Category: Research Source Type: clinical trials
Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint Inhibitors
Condition: Hepatocellular Carcinoma Intervention: Drug: Anlotinib and TQB2450 Sponsors: Shanghai Zhongshan Hospital; Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 11, 2023 Category: Research Source Type: clinical trials
Sorafenib In Egyptian Patients With Hepatocellular Carcinoma.
Condition: Hepatocellular Carcinoma Intervention: Drug: Sorafenib Tablets Sponsors: Damanhour University; Mransoura University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 11, 2023 Category: Research Source Type: clinical trials
Usability and Clinical Effectiveness of an Interpretable Deep Learning Framework for Post-Hepatectomy Liver Failure Prediction
Conditions: Post-hepatectomy Liver Failure; Hepatocellular Carcinoma; Artificial Intelligence Interventions: Other: The explanation of deep learning framework (VAE-MLP) , including counterfactual explanations and layerwise relevance propagation; Other: The model prediction; Other: The model prediction and the explanation of deep learning framework (VAE-MLP) , including counterfactual explanati ons and layerwise relevance propagation Sponsors: Maastricht University; First Affiliated Hospital, Sun Yat-Sen University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 11, 2023 Category: Research Source Type: clinical trials
Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint Inhibitors
Condition: Hepatocellular Carcinoma Intervention: Drug: Anlotinib and TQB2450 Sponsors: Shanghai Zhongshan Hospital; Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 11, 2023 Category: Research Source Type: clinical trials
Sorafenib In Egyptian Patients With Hepatocellular Carcinoma.
Condition: Hepatocellular Carcinoma Intervention: Drug: Sorafenib Tablets Sponsors: Damanhour University; Mransoura University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 11, 2023 Category: Research Source Type: clinical trials
Usability and Clinical Effectiveness of an Interpretable Deep Learning Framework for Post-Hepatectomy Liver Failure Prediction
Conditions: Post-hepatectomy Liver Failure; Hepatocellular Carcinoma; Artificial Intelligence Interventions: Other: The explanation of deep learning framework (VAE-MLP) , including counterfactual explanations and layerwise relevance propagation; Other: The model prediction; Other: The model prediction and the explanation of deep learning framework (VAE-MLP) , including counterfactual explanati ons and layerwise relevance propagation Sponsors: Maastricht University; First Affiliated Hospital, Sun Yat-Sen University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 11, 2023 Category: Research Source Type: clinical trials
Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint Inhibitors
Condition: Hepatocellular Carcinoma Intervention: Drug: Anlotinib and TQB2450 Sponsors: Shanghai Zhongshan Hospital; Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 11, 2023 Category: Research Source Type: clinical trials
Sorafenib In Egyptian Patients With Hepatocellular Carcinoma.
Condition: Hepatocellular Carcinoma Intervention: Drug: Sorafenib Tablets Sponsors: Damanhour University; Mransoura University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 11, 2023 Category: Research Source Type: clinical trials
Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint Inhibitors
Condition: Hepatocellular Carcinoma Intervention: Drug: Anlotinib and TQB2450 Sponsors: Shanghai Zhongshan Hospital; Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 11, 2023 Category: Research Source Type: clinical trials
Usability and Clinical Effectiveness of an Interpretable Deep Learning Framework for Post-Hepatectomy Liver Failure Prediction
Conditions: Post-hepatectomy Liver Failure; Hepatocellular Carcinoma; Artificial Intelligence Interventions: Other: The explanation of deep learning framework (VAE-MLP) , including counterfactual explanations and layerwise relevance propagation; Other: The model prediction; Other: The model prediction and the explanation of deep learning framework (VAE-MLP) , including counterfactual explanati ons and layerwise relevance propagation Sponsors: Maastricht University; First Affiliated Hospital, Sun Yat-Sen University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 11, 2023 Category: Research Source Type: clinical trials
Sorafenib In Egyptian Patients With Hepatocellular Carcinoma.
Condition: Hepatocellular Carcinoma Intervention: Drug: Sorafenib Tablets Sponsors: Damanhour University; Mransoura University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 11, 2023 Category: Research Source Type: clinical trials
Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study
Condition: HCC Intervention: Drug: TACE Sponsor: Zhongda Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 6, 2023 Category: Research Source Type: clinical trials